| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-027 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事、实际控制人增持公司股份计划的公告 董事、实际控制人李振平先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2、增持主体持股情况：本次增持计划实施前，李振平先生直接持有公司股份 5,552,618 股，占公司现总股本的 0.55%，并通过淄博蓝帆投资有限公司持有公司股份 234,781,123 股，占公司现总股本的 23.31%。 3、李振平先生在本次公告披露前 12 个月内未披露增持计划，在本次公告披露前 6 个月内不存在减持公司股份的情形。 二、增持计划的主要内容 1、增持目的：基于对公司内在价值的认可和未来持续稳定健康发展的坚定信心， 以及维护股东利益和增强投资者信心，李振平先生拟增持公司股份。 2、增持股份的数量或金额：本次计划增持金额不低于人民币 2,000 万元（含）。 3、增持 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-026 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于2026年第一季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 证券代码：002382，证券简称：蓝帆医疗 债券代码：128108，债券简称：蓝帆转债 转股价格：人民币 9.50 元/股、8.50 元/股（2026 年 1 月 27 日生效）、7.95 元/股（2026 年 3 月 17 日生效） 经深圳证券交易所（以下简称"深交所"）"深证上〔2020〕523 号"文同意，公司 314,404 万元可转债于 2020 年 6 月 19 日起在深交所挂牌交易，债券简称"蓝帆转债"，债券代 码"128108"。 转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 根据《深圳证券交易所股票上市规则》、《深圳证券交易所可转换公司债券交易 实施细则》的有关规定，蓝帆医疗股份有限公司（以下简称"公司" ...

Summary of Conference Call Notes Industry Overview - The report focuses on the pharmaceutical raw materials and nitrile gloves industries, highlighting pricing trends and supply chain dynamics [1][2]. Key Points on Pharmaceutical Raw Materials - The raw material supply side entered a capacity digestion phase in 2023, with no new marginal changes expected after 2025, leading to a slow price transmission trend in the industry [1]. - Downstream customer inventories are at historical lows, driven by a "buy high, sell low" mentality, which is expected to trigger a replenishment cycle, ensuring the sustainability of price increases [1][3]. - Significant price increases have been observed in antibiotics like 6-APA and petroleum-related products (calcium pantothenate, vitamin E), with price turning points for sartans expected in the second half of 2026 [1][5]. - The raw material pharmaceutical companies are expected to maintain stable gross margins due to the presence of low-cost inventory and the long supply chain, which mitigates the impact of upstream cost increases [3][4]. Investment Recommendations in Pharmaceutical Raw Materials - Companies with a high proportion of raw material pharmaceuticals, such as Prologis and Tianyu Co., are recommended for their potential profit elasticity during this price increase cycle [1][5]. Key Points on Nitrile Gloves Industry - The nitrile gloves industry is expected to see significant profit elasticity starting in Q2 2026, driven by rising raw material prices, particularly butadiene and nitrile latex [1][6]. - The supply is concentrating among leading companies as smaller manufacturers face cost pressures and may cease operations, while leading firms benefit from long-term supply agreements [7][8]. - The demand for nitrile gloves remains rigid, especially in the medical sector, which accounts for over 60% of usage, and distributors are likely to increase stockpiling in response to rising prices [7][8]. Price Trends and Supply Chain Dynamics in Nitrile Gloves - The price of nitrile latex, which constitutes about 63% of production costs, has surged from over 5,000 RMB per ton to over 9,000 RMB per ton since late February 2026, with butadiene prices also experiencing a significant increase [8]. - The price transmission from raw materials to finished nitrile gloves is expected to exceed the increase in raw material prices, indicating a strong upward trend in final product pricing [8][10]. Global Market Dynamics for Nitrile Gloves - The global demand for disposable gloves is stabilizing after a period of rapid growth during the pandemic, with a projected steady growth rate in the coming years [9]. - Over 90% of global production capacity is concentrated in China and Malaysia, with leading domestic companies like YK Medical and Blue Sail Medical expected to increase their market share due to lower production costs compared to Malaysian competitors [9]. Future Trends and Strategic Moves - The export prices of nitrile gloves are at historical lows due to tariffs affecting the U.S. market, but an increase in raw material prices is expected to lead to significant price hikes in the near future [10][11]. - The establishment of overseas production bases in Southeast Asia is crucial for restoring and expanding market share in the U.S., with companies like YK Medical and Zhonghong Medical accelerating their investments in this region [11]. Key Indicators for Investors - Investors should monitor the following indicators: 1. Changes in upstream raw material prices, particularly nitrile latex and butadiene [12]. 2. Order price adjustments by leading companies in both domestic and U.S. markets [12]. 3. Inventory levels and stockpiling trends among distributors [12]. 4. Progress in domestic and foreign companies' expansion in Southeast Asia [12].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-024 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于部分董事、高级管理人员增持公司股份计划实施完成 士分别出具的《关于增持股份计划实施结果的告知函》，现将相关情况公告如下： 一、增持主体的基本情况 1、增持主体的基本情况：董事长刘文静女士，董事、总裁钟舒乔先生，董事于苏 华先生，职工董事赵敏女士，副总裁、首席财务官崔运涛先生，董事会秘书王梓漪女士。 | 姓名 | 职务 | 持有股份数量（股） | 占公司总股本比例（%） | | --- | --- | --- | --- | | 刘文静 | 董事长 | 3,680,700 | 0.37 | | 钟舒乔 | 董事、总裁 | 439,000 | 0.04 | | 于苏华 | 董事 | 192,000 | 0.02 | | 赵敏 | 职工董事 | - | - | | 崔运涛 | 副总裁、首席财务官 | - | - | | 王梓漪 | 董事会秘书 | - | - | 的公告 董事长刘文静女士，董事、总裁钟舒乔 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-025 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司为子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2025年12月12日召开了第六届董 事会第三十五次会议、2025年12月29日召开了2025年第七次临时股东会，审议并通过 了《关于2026年度申请授信及担保额度预计的议案》，公司及子公司2026年度拟向银 行等金融机构申请综合授信总额不超过人民币30亿元，授信品种包括但不限于流动资 金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综合授信业务（具 体业务品种以相关金融机构审批为准），具体融资金额将视公司及子公司生产运营对 资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述综合授信提供担 保额度总计不超过人民币30亿元，担保方式包括但不限于连带责任担保、股权质押、 资产抵押、 ...

Group 1 - Premier Li Qiang emphasized that China's competitive advantages come from deepening reforms and innovation, not subsidies or protectionism, and highlighted the importance of fair competition in the market economy [4] - Central Bank Governor Pan Gongsheng stated that the People's Bank of China will maintain a supportive monetary policy stance to create a favorable environment for stable economic growth and high-quality development [4] - The National Internet Emergency Center and the China Cybersecurity Association released security guidelines for the use of OpenClaw, providing recommendations for ordinary users and cloud service providers [5] Group 2 - The China Development Forum 2026 released multiple policy signals, indicating a focus on high-quality development and global economic stability [6] - The Chinese automotive industry achieved a significant milestone by surpassing Japan in global annual sales for the first time, with nearly 27 million vehicles sold [17] - The Ministry of Finance plans to increase public service spending and implement consumer-friendly policies to stimulate domestic demand, including a special fund of 100 billion yuan to promote consumption [9][10] Group 3 - The latest findings from the Ministry of Natural Resources revealed a significant increase in rare earth resources in Sichuan, with verified reserves totaling 9.67 million tons, marking an over 200% increase compared to previous estimates [18] - The launch of the "TERAFAB" chip manufacturing project by Tesla aims to achieve an annual production capacity of over 1 terawatt, with an estimated total investment of $20 billion [21] - Apple CEO Tim Cook announced continued support for innovation and education in China, pledging additional donations to a national vocational education pilot project [22]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The healthcare insurance fund is operating smoothly, with a total income of CNY 3.59 trillion and total expenditure of CNY 3 trillion in 2025, reflecting a stable operation of the fund [6][12]. - The report highlights the importance of focusing on sectors with individual stock alpha or defensive attributes amid increased market volatility due to external shocks [6][12]. - The report emphasizes the potential for price increases in the pharmaceutical sector, particularly in innovative drugs and high-end medical devices, supported by healthcare insurance policies [12]. - NVIDIA's GTC 2026 outlines a comprehensive strategy for integrating AI into the healthcare industry, indicating a significant transformation in the medical value chain [12][19]. Summary by Sections Industry Overview - The pharmaceutical and biotechnology sector has a total market capitalization of CNY 67,613.55 billion and a circulating market value of CNY 61,920.43 billion, with 504 listed companies [2]. Market Dynamics - The report notes that the Shanghai Composite Index fell by 2.19% and the pharmaceutical sector declined by 2.77%, ranking 8th among 31 sub-industries [6][19]. - The report identifies that the performance of individual stocks varies, with companies like Dong-E E-Jiao and China Resources Sanjiu showing positive profit growth [12]. Company Performance - Key recommended stocks include WuXi Biologics, Tigermed, and Sihuan Pharmaceutical, all rated as "Buy" [4]. - The report highlights the performance of specific companies, such as Sanofi and Jizhong Pharmaceutical, which have shown significant weekly gains [28]. Valuation Metrics - The pharmaceutical sector is currently valued at 21.9 times PE based on 2026 earnings forecasts, with a premium of 11% over the overall A-share market [21][22]. - The TTM valuation for the sector stands at 29.9 times PE, below the historical average of 34.8 times PE, indicating potential undervaluation [21][22].

Summary of the Conference Call for 蓝帆医疗 Industry Overview - The nitrile glove industry is experiencing a collective price increase, with international peers expecting order prices to rise by $7-9. Domestic companies benefit from diversified energy structures and stable supply chains, leading to a significant cost advantage over overseas competitors [2][3]. - 蓝帆医疗 has secured nitrile latex supply until June 2026, while competitors without early arrangements face over 50% raw material cost increases [2][4]. Company Insights - 蓝帆医疗 has a production capacity of 250 million nitrile gloves and 250 million PVC gloves. The Shandong base has the potential to expand nitrile glove production by 10 billion, with 4 billion available for rapid release based on demand [2][5]. - The gross margin for the cardiovascular business remains around 65%, with the rapamycin drug balloon capturing nearly 90% of the national procurement market. The overseas TAVR products are entering a growth phase, with growth in the first two months of 2026 exceeding the average for the entire year of 2025 [2][8]. - The emergency rescue segment maintains a gross margin below 30%, benefiting from a five-year mandatory replacement cycle for vehicle-mounted first aid kits in Europe and new regulatory demands in emerging markets [2][11]. Market Dynamics - A significant inventory depletion among overseas clients is expected by mid-April 2026, which will clarify market acceptance of price increases and drive industry profit levels back [2][7]. - The global supply of nitrile latex is concentrated in East Asia, with domestic suppliers maintaining a stable supply chain compared to international competitors facing shortages due to reliance on upstream raw materials [3][4]. Pricing Strategy - The company can lock in prices to some extent through strategic procurement, which provides a cost advantage over competitors who rely on spot purchases. Without proactive procurement, costs could rise significantly [4][5]. - Customers are generally accepting of price increases, especially in the medical sector where demand is inelastic. Price thresholds for switching to PVC gloves are debated, with estimates ranging from $25 to $30 [5][6]. Production Expansion Plans - The company has flexible production capacity and plans to prioritize existing capacity before considering overseas expansion. The Shandong base is ready for rapid expansion to meet rising demand [6][10]. - The strategy includes leveraging existing production capabilities to enhance profitability before planning overseas investments, given the current geopolitical uncertainties [6][10]. Competitive Landscape - The cardiovascular sector is facing a shift towards centralized procurement, which may affect pricing across various medical fields. The company is well-positioned to adapt to these changes due to its understanding of the industry and product portfolio [7][8]. - The market for TAVR products is competitive, with many players, but the company has strategically focused on overseas markets to ensure profitability and scale [9][10]. Emergency Rescue Segment - The emergency rescue product market is driven by mandatory regulations in developed countries, creating a stable demand for first aid kits. The company is expanding its presence in emerging markets where regulations are being established [10][11]. - The gross margin for the emergency rescue segment remains stable at around 30%, with variations based on regional pricing strategies [11].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-023 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于部分董事、高级管理人员增持公司股份计划的公告 董事长刘文静女士，董事、总裁钟舒乔先生，董事于苏华先生，职工董事赵敏女士， 副总裁、首席财务官崔运涛先生，董事会秘书王梓漪女士保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：基于对蓝帆医疗股份有限公司（以下简称"公司"）内在价值的认可和 未来持续稳定健康发展的坚定信心，以及维护股东利益和增强投资者信心，公司董事长 刘文静女士，董事、总裁钟舒乔先生，董事于苏华先生，职工董事赵敏女士，副总裁、 首席财务官崔运涛先生，董事会秘书王梓漪女士拟自本增持计划公告之日起1周内（2026 年 3 月 20 日-2026 年 3 月 26 日），按照相关法律法规的规定增持公司股份，本次计划增 持金额合计不低于人民币 500 万元（含）。 公司于近日接到董事长刘 ...

Summary of the Conference Call for 蓝帆医疗 (Blue Sail Medical) Company Overview - **Company**: 蓝帆医疗 (Blue Sail Medical) - **Industry**: Medical Devices, specifically focusing on cardiovascular products and protective gloves Key Points Industry and Business Performance - **Cardiovascular Business**: Expected to turn profitable by 2025, with a focus on expanding hospital coverage to over 3,000 and achieving a million-level implant volume. Self-developed products are projected to account for 50% of sales, with gross margins potentially recovering to over 60% [2][4] - **Protective Gloves Business**: Anticipated to achieve stable profitability by Q1 2026, driven by geopolitical factors and raw material price increases. Prices for nitrile gloves are expected to rise by over $7 per box, and PVC gloves by $2-3 per box [2][7] - **Investment in Thailand**: A $200 million investment from Thailand aims to address energy cost issues by acquiring a local power plant and constructing a new facility, which will significantly reduce production costs [2][5] Financial Performance and Projections - **Historical Losses**: The company faced losses from 2021 to 2024, with amounts of 400 million, 300 million, 200 million, and 100 million respectively. Strategies to mitigate losses include expanding market access and increasing self-developed product sales [4][6] - **Future Profitability**: By 2025, the company expects to achieve profitability exceeding 100 million, with a gross margin recovery to 60% [4][6] Strategic Initiatives - **Forward Stockpiling Strategy**: The company has stockpiled low-cost nitrile latex to benefit from price increases expected in 2026, with inventory sufficient until May 2026 [2][7][11] - **International Expansion**: The cardiovascular business is expanding internationally, with an overseas sales team of over 200 people and projected overseas revenue exceeding 800 million RMB by 2025 [2][12] Challenges and Responses - **Energy Costs**: High energy costs have been a significant challenge. The investment from Thailand is expected to alleviate this issue by integrating energy supply and improving production efficiency [5][6] - **Market Dynamics**: The company is navigating a challenging market environment, including price fluctuations due to geopolitical tensions and tariff policies [4][5][18] Market Trends and Pricing - **Price Increases**: The company anticipates significant price increases in gloves due to raw material cost pressures and market dynamics, with nitrile gloves expected to see a price increase of $7 or more per box [7][22] - **Demand Resilience**: Despite price increases, demand for gloves remains strong, with inventory levels low and customers expected to replenish stock quickly [15][22] Future Outlook - **High-Quality Development Cycle**: The company is entering a new growth phase, benefiting from demographic trends and increasing disease prevalence. The cardiovascular sector is expected to grow at double-digit rates [4][30] - **Strategic Partnerships**: The company is focusing on strategic partnerships and investments to enhance its product offerings and market presence, particularly in the cardiovascular space [12][30] Conclusion - **Long-term Vision**: 蓝帆医疗 aims to become a respected global company in the medical field, leveraging its experience and strategic initiatives to navigate challenges and capitalize on growth opportunities [30][31]